Antibody-Drug Conjugates (ADCs) combine the specificity of monoclonal antibodies with the potent cytotoxic effects of small molecule drugs. Due to the sophisticated nature of these new modalities, both the challenges and the costs of development are higher compared to more traditional therapeutics. Optimizing solubility early can positively impact development by improving ADC stability, pharmacokinetics, manufacturability, and therapeutic performance.
Insoluble ADCs cause:
Soluble ADCs enable:
Allocating enough resources to thoroughly investigate the solubility profiles of ADC components during the early stages of development optimizes downstream processes and prevents attrition. By modifying the payload and choosing a linker to increase the solubility of an ADC without compromising potency – stability, pharmacokinetics, manufacturability, and therapeutic performance can all be enhanced from the onset – talk to our experts.
If you’re looking to Research Smart and Deliver Early, click here to drop us a message!
Viikinkaari 4
00790 Helsinki
FINLAND
1 Broadway
Cambridge MA 01242
United States
Workshop: Mitigating Risk in Small Molecule Drug Development
6 February 2025, MassBioHub, Cambridge, MA